A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
Epistemonikos ID: 87a997ca91f64a00033d2476e4758eecfd68d6ae
First added on: May 15, 2024